Severity of Plasma Leakage Is Associated With High Levels of Interferon {gamma}-Inducible Protein 10, Hepatocyte Growth Factor, Matrix Metalloproteinase 2 (MMP-2), and MMP-9 During Dengue Virus Infection
Conclusions. This study identified several key markers for exacerbated dengue pathogenesis, notably plasma leakage. This will allow a better understanding of the molecular mechanisms of DHF and DSS in patients with dengue. (Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - January 9, 2017 Category: Infectious Diseases Authors: Her, Z., Kam, Y.-W., Gan, V. C., Lee, B., Thein, T.-L., Tan, J. J. L., SIgN Immunomonitoring Platform, Lee, L. K., Fink, K., Lye, D. C., Renia, L., Leo, Y.-S., Ng, L. F. P. Tags: VIRUSES Source Type: research
Significant Correlation Between the Infant Gut Microbiome and Rotavirus Vaccine Response in Rural Ghana
Conclusions. The intestinal microbiome composition correlates significantly with RVV immunogenicity and may contribute to the diminished RVV immunogenicity observed in developing countries. (Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - January 9, 2017 Category: Infectious Diseases Authors: Harris, V. C., Armah, G., Fuentes, S., Korpela, K. E., Parashar, U., Victor, J. C., Tate, J., de Weerth, C., Giaquinto, C., Wiersinga, W. J., Lewis, K. D. C., de Vos, W. M. Tags: VIRUSES Source Type: research
A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant
Conclusions. The RSV-PreF vaccine elicited rapid RSV neutralizing antibody responses in healthy young men, with an acceptable adverse event profile. (Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - January 9, 2017 Category: Infectious Diseases Authors: Langley, J. M., Aggarwal, N., Toma, A., Halperin, S. A., McNeil, S. A., Fissette, L., Dewe, W., Leyssen, M., Toussaint, J.-F., Dieussaert, I. Tags: VIRUSES Source Type: research
Clinical and Socioeconomic Burden of Respiratory Syncytial Virus Infection in Children
Conclusions. The burden of RSV is particularly great among outpatient children aged <3 years. Young children are an important target group for the development of RSV vaccines and antivirals. (Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - January 9, 2017 Category: Infectious Diseases Authors: Heikkinen, T., Ojala, E., Waris, M. Tags: VIRUSES Source Type: research
Reducing Health Regrets in a Changing Climate
(Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - January 9, 2017 Category: Infectious Diseases Authors: Levy, K. Tags: PERSPECTIVE Source Type: research
Redeploying {beta}-Lactams Against Staphylococcus aureus: Repurposing With a Purpose
(Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - January 9, 2017 Category: Infectious Diseases Authors: Bayer, A. S., Xiong, Y. Q. Tags: EDITORIAL COMMENTARIES Source Type: research
The Gut Microbiome as Possible Key to Understanding and Improving Rotavirus Vaccine Performance in High-Disease Burden Settings
(Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - January 9, 2017 Category: Infectious Diseases Authors: Iturriza-Gomara, M., Cunliffe, N. A. Tags: EDITORIAL COMMENTARIES Source Type: research
Vaccines Against Respiratory Syncytial Virus: The Time Has Come
(Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - January 9, 2017 Category: Infectious Diseases Authors: Englund, J. A., Chu, H. Y. Tags: EDITORIAL COMMENTARIES Source Type: research
The Outpatient Burden of Respiratory Syncytial Virus Infections in Older Children
(Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - January 9, 2017 Category: Infectious Diseases Authors: Simoes, E. A. F. Tags: EDITORIAL COMMENTARIES Source Type: research
Chikungunya in the Americas: Recommendations and Conclusions
Discovered in 1953, chikungunya virus (CHIKV) circulated in Africa and Southeast Asia, with periodic outbreaks, for many years. Highly efficient transmission following a genetic mutation of the virus in 2005 caused its global spread. Associated with significant morbidity, CHIKV creates a large public health burden, and despite various efforts, there are currently no licensed vaccines nor specific treatments. To garner a better understanding of the virus, identify gaps in knowledge, and guide the development of more-effective interventions, the World Health Organization and National Institute of Allergy and Infectious Disea...
Source: The Journal of Infectious Diseases - December 4, 2016 Category: Infectious Diseases Authors: Graham, B. S., Repik, P. M., Yactayo, S. Tags: CHIKUNGUNYA Source Type: research
Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that is responsible for considerable epidemics worldwide and recently emerged in the Americas in 2013. CHIKV may cause long-lasting arthralgia after acute infection. With currently no licensed vaccines or antivirals, the design of effective therapies to prevent or treat CHIKV infection is of utmost importance and will be facilitated by increased understanding of the dynamics of chikungunya. In this article, monoclonal antibodies against CHIKV as viable prophylactic and therapeutic agents will be discussed. (Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - December 4, 2016 Category: Infectious Diseases Authors: Clayton, A. M. Tags: CHIKUNGUNYA Source Type: research
Chikungunya Virus Vaccines: Viral Vector-Based Approaches
In 2013, a major chikungunya virus (CHIKV) epidemic reached the Americas. In the past 2 years, >1.7 million people have been infected. In light of the current epidemic, with millions of people in North and South America at risk, efforts to rapidly develop effective vaccines have increased. Here, we focus on CHIKV vaccines that use viral-vector technologies. This group of vaccine candidates shares an ability to potently induce humoral and cellular immune responses by use of highly attenuated and safe vaccine backbones. So far, well-described vectors such as modified vaccinia virus Ankara, complex adenovirus, vesicular st...
Source: The Journal of Infectious Diseases - December 4, 2016 Category: Infectious Diseases Authors: Ramsauer, K., Tangy, F. Tags: CHIKUNGUNYA Source Type: research
Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus
Chikungunya virus (CHIKV) is a global public health threat, having been identified in >60 countries in Asia, Africa, Europe, and the Americas. There is no cure for or licensed vaccine against CHIKV infection. Initial attempts at CHIKV vaccine development began in the early 1960s. Whole-inactivated and virus-like particle (VLP) vaccines are 2 of the current approaches being evaluated. Success of these approaches is dependent on a safe, well-tolerated vaccine that is immunogenic and deployable in regard to manufacturing, stability, and delivery characteristics. (Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - December 4, 2016 Category: Infectious Diseases Authors: DeZure, A. D., Berkowitz, N. M., Graham, B. S., Ledgerwood, J. E. Tags: CHIKUNGUNYA Source Type: research
Development of Vaccines for Chikungunya Fever
Chikungunya fever, an acute and often chronic arthralgic disease caused by the mosquito-borne chikungunya virus (CHIKV), has reemerged since 2004 to cause millions of cases. Because CHIKV exhibits limited antigenic diversity and is not known to be capable of reinfection, a vaccine could serve to both prevent disease and diminish human amplification during epidemic circulation. Here, we review the many promising vaccine platforms and candidates developed for CHIKV since the 1970s, including several in late preclinical or clinical development. We discuss the advantages and limitations of each, as well as the commercial and r...
Source: The Journal of Infectious Diseases - December 4, 2016 Category: Infectious Diseases Authors: Erasmus, J. H., Rossi, S. L., Weaver, S. C. Tags: CHIKUNGUNYA Source Type: research
Animal Models of Chikungunya Virus Infection and Disease
Chikungunya virus (CHIKV) is a reemerging alphavirus that causes acute febrile illness and severe joint pain in humans. Although acute symptoms often resolve within a few days, chronic joint and muscle pain can be long lasting. In the last decade, CHIKV has caused widespread outbreaks of unprecedented scale in the Americas, Asia, and the Indian Ocean island regions. Despite these outbreaks and the continued expansion of CHIKV into new areas, mechanisms of chikungunya pathogenesis and disease are not well understood. Experimental animal models are indispensable to the field of CHIKV research. The most commonly used experime...
Source: The Journal of Infectious Diseases - December 4, 2016 Category: Infectious Diseases Authors: Haese, N. N., Broeckel, R. M., Hawman, D. W., Heise, M. T., Morrison, T. E., Streblow, D. N. Tags: CHIKUNGUNYA Source Type: research
